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Protocol
AbstrACt
Introduction We will use the existing online mechanisms 
of the Treatment in Morning versus Evening (TIME) 
study to collect patient-reported outcome measures of 
sleep quality to determine whether nocturnal dosing of 
antihypertensives affects sleep quality, when compared 
with morning dosing. The TIME study aims to determine 
if morning or evening dosing of antihypertensive 
medications is more effective in preventing heart attacks 
and strokes. The cardiovascular end points in TIME are 
identified by individual-level linkage to routinely collected 
hospital admissions and mortality data; these data are 
supplemented with participant-completed follow-up 
questionnaires, administered online. This substudy will 
provide information regarding the relative acceptability 
of morning and evening dosing of antihypertensives that 
will be essential should the TIME study results prompt 
doctors to consider advising particular dosing times to 
their patients.
Methods and analysis TIME participants are aged over 
18 years and prescribed at least one antihypertensive 
drug, taken once a day. They are self-enrolled and 
consented on the secure TIME website (www. timestudy. co. 
uk) and then randomised to dosing time. Study follow-up is 
conducted by automated email. Average participant follow-
up is expected to be 4 years. Participants in the sleep 
substudy are asked to complete an online sleep quality 
questionnaire at baseline, after 3 months and annually. This 
includes a Pittsburgh Sleep Quality Index (PSQI), a Hospital 
Anxiety and Depression Scale and an Epworth Sleepiness 
Scale. The primary outcome of the TIME Sleep substudy 
is sleep quality as measured by the PSQI. Secondary 
outcomes include sleep quantity and duration, and an 
analysis of any association between sleep quality and the 
main outcome measures of the TIME study (heart attack, 
stroke and vascular death).
Ethics and dissemination Ethical approval has been 
obtained from the Tayside Committee on Medical Research 
Ethics (MREC reference: 11/AL/0309), and results will be 
published in a peer-reviewed journal.
Protocol version 9 (approved 19 July 2017). 
trial registration number UKCRN ID: 17071. ISRCTN: 
18157641. Pre-results. 
IntroduCtIon
The Treatment In Morning versus Evening 
(TIME) study is a single-centre, online, paral-
lel-group randomised controlled trial aiming 
to determine if morning or evening dosing 
of antihypertensive medications is better in 
terms of preventing heart attacks and strokes. 
It is not known what effect, if any, evening 
dosing of antihypertensives will have on sleep 
duration and quality. Significant adverse 
effects on sleep may greatly reduce the accep-
tance of any subsequent recommendation 
regarding antihypertensive dosing time.
Patient-reported outcome measures 
(PROMs) are increasingly being adopted by 
healthcare organisations1 and researchers2 
as a way to demonstrate the effectiveness of 
interventions on outcomes that are best deter-
mined by patients themselves. Sleep quality is 
one such outcome that may have a bearing on 
any future application of dosing time guid-
ance. Despite their potential, there are chal-
lenges associated with the administration of 
PROMs in clinical trials such as missing data 
strengths and limitations of this study
 ► This substudy will provide participant-derived infor-
mation on the acceptability of morning and evening 
dosing of usual antihypertensives.
 ► The study uses an online patient-reported outcome 
measure to supplement a clinical primary end point.
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and inconsistent implementation. Early study dropout 
can be problematic when study participants are left to 
complete lengthy paper questionnaires without support 
or guidance. It has been suggested that electronic admin-
istration of PROMs may reduce such problems by auto-
mating reminders, standardising responses and allowing 
mandatory data fields.3 In this substudy, we aim to use the 
existing online follow-up mechanisms of the TIME study 
to collect PROMs of sleep quality. These will be used to 
determine whether nocturnal dosing of antihyperten-
sives affects sleep quality, when compared with morning 
dosing.
The background to the main TIME trial is detailed in 
the main study protocol and is not repeated here.4 Links 
between sleep characteristics and hypertension have been 
extensively demonstrated.5 In particular, sleep disordered 
breathing, such as obstructive sleep apnoea, is an important 
cause of secondary hypertension and associated with 
increased cardiovascular risk.6 Furthermore, poor sleep 
quality and quantity have been shown to be associated with 
hypertension and the non-dipping phenomenon. Non-dip-
ping describes a lack of the normal pattern of blood pres-
sure lowering at night and has been found to be associated 
with increased risk of cardiovascular events in hypertensive 
patients.7 Non-dipping hypertensive patients are more likely 
to report poor sleep quality.8The Saga Challenge Antihyper-
tensive Study (S-CATS) suggested that effective hyperten-
sion treatment (with losartan and hydrochlorothiazide) also 
resulted in improvements in overall quality of life and sleep 
quality.9 The TIME study is based on research that suggests 
that evening dosing may be more effective at improving 
cardiovascular outcomes.10 One proposed explanation for 
this effect is that evening dosing of antihypertensives may 
restore the physiological nocturnal dipping pattern.11 If 
this is the case then we might also expect evening admin-
istration of antihypertensive medication to result in some 
improvement in sleep quality. Conversely, some antihyper-
tensive treatments have known adverse effects—that could 
be expected to worsen sleep quality when administered 
close to bedtime: polyuria caused by diuretics may increase 
night waking, and lipophilic beta-blockers have been impli-
cated in parasomnia behaviours.12–14
MEthods
trial design
The TIME study is a parallel-group randomised controlled 
cardiovascular event outcome trial of people with treated 
hypertension. It aims to compare morning and evening 
dosing times of usual antihypertensive medication with a 
primary composite outcome of hospitalised heart attack, 
hospitalised stroke and vascular death. TIME is an online 
study with participants taking part via a secure study-spe-
cific electronic case report form.
The TIME Sleep substudy invites newly consented 
TIME study participants to complete an online sleep 
quality questionnaire at baseline (within 1 week of TIME 
study randomisation), 3 months and annually. The 
questionnaire comprises the Pittsburgh Sleep Quality 
Index (PSQI), Hospital Anxiety and Depression Scale 
(HADS) and the Epworth Sleepiness Scale (ESS).
Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index (PSQI) is a validated 
scoring system that has been used in many different clinical 
and research situations. It has been found to be effective 
at identifying poor sleep quality and detecting change in 
sleep quality. The PSQI overall score discriminates between 
‘good’ and ‘poor’ sleepers. It also captures self-reported 
measures of sleep duration. The global score for the 
PSQI ranges from 0 to 21 with scores >5 having a sensi-
tivity of 89.6% and specificity of 86.5% in identifying poor 
sleepers15 16 (see online supplementary appendix 1).
Hospital Anxiety and Depression Scale
Disordered mood is associated with poor sleep quality.17 
In order to take this into account as a potential covariate 
in the final study analysis, participants were asked to 
complete a HADS. The HADS is a short (14-item) ques-
tionnaire that was first published in 1983 as a screening 
tool for depression and anxiety in general hospital 
populations.18 The tool has since been validated in 
many different clinical and community settings19 (see 
online supplementary appendix 2).
The Epworth Sleepiness Scale
The ESS is a short, self-administered, questionnaire that 
is widely used to assess daytime sleepiness. It is often 
used in clinical settings as a screening test for sleep disor-
ders such as obstructive sleep apnoea syndrome20 21 (see 
online supplementary appendix 3).
recruitment strategy
From August 2015 onwards, newly enrolled participants in 
the TIME study were offered the opportunity to volunteer 
for the sleep-quality substudy soon after they consented 
to take part in the main trial.
Intervention
Participants within the TIME study are randomly allocated 
to either morning or evening dosing of their usual anti-
hypertensive medications. Subjects allocated to morning 
dosing are advised to take all of their blood pressure-low-
ering medications between 06:00 and 10:00 hours (and 
as soon after waking as practicable) throughout the study. 
Those allocated to evening dosing are instructed to take all 
their blood pressure-lowering medications between 20:00 
and 24:00 hours (and as late before retiring as is prac-
ticable). There is no other intervention in the study and 
participants continue to attend their usual GP or outpatient 
clinic for routine hypertension follow-up. The only addi-
tional intervention within the sleep substudy is the ques-
tionnaires as described above.
Follow-up
TIME participants are asked by email to complete an 
online follow-up questionnaire every 3 months. This 
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questionnaire collects data on compliance, side effects 
and potential cardiovascular end point events. Additional 
sleep substudy follow-up email requests are sent 3 months 
after baseline sleep questionnaire submission and then 
annually.
Consenting participants
TIME participants were free to accept or decline the invi-
tation to take part in the sleep substudy. To support their 
decision making, a patient information sheet was provided 
with the invitation containing detailed information about 
the substudy (see online supplementary appendix 4). All 
potential substudy participants have already completed 
an electronic consent form for the TIME study. They are 
asked to complete a further short online consent form 
for the substudy (see online supplementary appendix 5). 
This consent process is conducted entirely via the study 
website without the active participation of study personnel 
in general, although participants are given opportunities 
to clarify or ask for more information.
data collection
The TIME Sleep substudy does not collect any additional 
data to the TIME study other than that obtained by the 
online sleep questionnaire.
Withdrawal
Subjects are free to withdraw from the TIME Sleep 
substudy at any point without affecting their participation 
in the TIME study overall.
randomisation
Computer randomisation
Randomisation to the TIME study is done centrally using 
randomly generated bits, which are then allocated to 
participants sequentially. Randomised status is confirmed 
by automated email sent to the participant. There is no 
further randomisation in the TIME Sleep substudy.
treatment allocation
Dosing time allocation is not blinded.
Patient and public involvement
The sleep-quality substudy was initially prompted by 
comments from TIME study participants about antic-
ipated or experienced changes in sleep quality on 
changing their dosage time. Patients were not involved 
in the design, recruitment or conduct of the study but 
feedback from study participants was used to improve the 
online user interface of the substudy. Results of the sleep-
quality substudy will be shared with participants by email.
study PoPulAtIon
Hypertensive patients aged 18 years or over, in the UK, 
prescribed one or more once-daily antihypertensive drug 
therapies, and, who have a valid email address.
trIAl End PoInts
The end points of the TIME study are detailed in the 
published protocol.4
Primary end point
The primary end point of the TIME Sleep substudy will 
be the proportion of participants reporting poor sleep 
quality (defined as PSQI>5) at 3 months.
secondary end points
 ► The proportion of participants reporting poor sleep 
quality at 1 year and annually.
 ► The proportion of participants reporting abnormal 
sleep duration at 3 months and annually.
 ► The mean change in sleep quality from baseline to 
3 months and annually.
 ► The mean change in sleep duration from baseline to 
3 months and annually.
We will also investigate whether any early changes in 
sleep quality or duration at 3 months are sustained in 
the long term and whether particular drug classes, for 
example, diuretics are more likely to affect sleep quality 
when taken at night than others. Additionally, we will 
determine if there is an association between non-ad-
herence to dosing time and reported sleep quality and 
duration.
AdvErsE EvEnts
The TIME study will collect adverse events associated with 
changing the time of dosing. These data will be collected 
during follow-up and at time of withdrawal from the study 
using standard online questionnaires. No additional 
adverse event reporting will be undertaken in the sleep 
substudy.
stAtIstICs And dAtA AnAlysIs
The primary analysis will be a comparison of sleep quality 
at 3 months in morning versus evening dosing. It will use 
a per-protocol cohort excluding patients who reported 
non-adherence to dose time allocation, died and/or 
were lost to follow-up. The outcome in this analysis (sleep 
quality defined as PQSI>5) is binary and we will use 
logistic regression to test for an effect of morning versus 
evening dosing, with baseline demographic variables 
(age, sex, systolic blood pressure, diastolic blood pres-
sure, total cholesterol, body mass index (BMI), smoking 
status), self-reported medical history (heart attack, stroke, 
diabetes), baseline medication use (diuretics, ACE inhibi-
tors, number of agents) and HADS score as covariates in 
the model.
Similar models will also be used for binary secondary 
outcomes. Change in sleep quality (PSQI score) and sleep 
duration will be treated as continuous variables with normal 
errors unless their distributions suggest this is inappro-
priate. We will test for interactions between any time of dose 
effect and medical history (previous myocardial infarction, 
 o
n




pen: first published as 10.1136/bmjopen-2018-021890 on 7 June 2018. Downloaded from 
4 Rogers A, et al. BMJ Open 2018;0:e021890. doi:10.1136/bmjopen-2018-021890
Open Access 
previous stroke, diabetes), class of antihypertensive medica-
tion and risk of sleep disordered breathing (using ESS, BMI, 
age and gender) will be performed. We will also correlate 
sleep data with TIME study outcomes (risk of heart attack, 
stroke of cardiovascular mortality) and assess whether any 
relationships are modified by dosing time.
data collection and retention
This substudy will only capture data directly from partici-
pants. Data will be validated at point of entry into the TIME 
database and before final analysis. All data will be held 
securely within the Medicines Monitoring Unit at Ninewells 
Hospital and Medical School. To enable evaluations and/
or audits, the investigators will keep records, including the 
identity of all participating patients, all original informed 
consent data, adverse event data and any source docu-
ments. The records will be securely retained and archived 
by the study sponsor according to ICH Good Clinical Prac-
tice (GCP) and local regulations.22 Participating subjects 
will be able to have sight of their own data on request and 
will be allowed to comment on perceived inaccuracies 
therein.
data protection
The study will comply with the requirements of the Data 
Protection Act 1998 with regard to the collection, storage, 
processing and disclosure of personal information and 
will uphold the Act’s core principles. Access to collated 
participant data will be restricted to appropriate study staff. 
Published results will not contain any personal data that 
could allow identification of individual participants.
sample size: evidence of feasibility and power calculation
This sleep substudy is powered for the primary analysis of 
the difference in the proportion of patients in each group 
with poor sleep quality at the 3-month follow-up. A previous 
study in a non-clinical population reported that 34.5% of 
subjects met the proposed cut-off of 5 on the PSQI scale 
for poor sleepers.23 Recruiting 1842 patients from each 
intervention group (3684 in total) will allow a difference 
in the proportion of patients reporting poor sleep of 5% 
between the two groups (30% vs 35%) with 90% power 
at the 5% level. Based on the current drop-out rate of the 
TIME study, 5%, we aimed to recruit 3878 people (actual 
recruitment was 3727 people). Such numbers would ensure 
that secondary analyses are amply powered when using the 
PSQI score as an outcome.
CoMPEtIng studIEs
We are not aware of any competing studies that would 
conflict with the TIME Sleep substudy.
Early stopping
If the event rate in the TIME study is higher than expected, 
or the TIME study Data Safety and Monitoring Board 
(DSMB) advise, then the trial may be stopped early. Sleep 
substudy data will not routinely be shared with the DSMB.
EthICs And dIssEMInAtIon
steering committee and independent data monitoring 
committee
The TIME steering committee oversees the appropriate 
scientific and ethical conduct of the trial, provides advice 
to the study sponsor, advises on the conduct and analysis 
of the study and approves all publications and substudies. 
The committee will operate through meetings, telecon-
ferences and e-mailings. The steering committee will be 
made up of invited experts, the chief investigator, the 
chair of the end point committee plus the coapplicants. 
The steering committee will meet at least annually. An 
independent data monitoring committee comprises 
experts in the field including clinicians with experience 
in hypertension and an expert trial statistician. The 
committee receives unblinded data and has the power to 
recommend modifications to the conduct of the study, 
including early discontinuation based on a risk/benefit 
assessment of the study data. It will meet at least annually 
and report to the steering committee.
sponsorship: monitoring, audit, quality control and quality 
assurance
The study sponsor is the University of Dundee who under-
takes monitoring and quality assurance. The TIME study 
is funded by the British Heart Foundation.
Protocol amendments
Changes in research activity, except those necessary to 
remove an apparent, immediate hazard, will be reviewed 
and approved by the chief investigator and sponsor. 
Amendments to the protocol will be submitted in writing 
for approval by the appropriate regulatory and ethical 
authorities prior to implementation.
Collaborating investigators
Collaborating investigators were responsible for dealing 
with the local issues of bringing the TIME trial to the 
attention of possible subjects either in clinics or in 
primary care.
Confidentiality
All data will be held securely with restricted access. Clin-
ical information will not be released without the written 
permission of the participant, except as necessary for 
auditing by the sponsor, its designee, regulatory author-
ities or the research ethics committee.
trial registration number
TIME is registered as ISRCTN: 18157641 and with a 
UKCRN ID: 17 071. The trial is performed in line with 
GCP guidelines and International Society of Pharmaco-
epidemiology Good Pharmacoepidemiology Practice 
Guidance.22 24
dissemination
The results of the trial will be published in a peer-reviewed 
scientific journal and made available to participants.
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dIsCussIon
There are some limitations to this methodology. The 
online version of the included PROMs has not been 
specifically validated against the original paper-based 
questionnaires. We endeavoured to minimise variation 
by closely replicating all questions and accompanying 
texts. The questionnaires were presented in single page 
format with the most significant difference from the 
original being the use of mandatory data fields to mini-
mise missing data. As with all patient-reported outcomes, 
the tests may be subject to bias with respondents able to 
inflate or minimise their answers. Ideally, we would have 
used actigraphy to assess the accuracy of self-reported 
sleep duration, but this was beyond the resources of the 
study. As the dosing time allocation in the TIME study is 
not blinded, this must be taken into account in the inter-
pretation of results. Only participants in the TIME study 
were eligible to take part. This means that the results of 
the substudy may not be generalisable; in particular, shift 
workers and those without a valid email address were 
excluded.
While observational data have found associations 
between sleep quality and duration and various cardio-
vascular diseases, the issue of how cardiovascular medi-
cations might affect sleep has not been widely explored. 
Additionally, case reports and cohort studies suggest that 
some specific blood pressure medications may be associ-
ated with sleep disturbance. The TIME Sleep substudy 
offers an opportunity to collect self-reported measures of 
sleep quality from a large trial population taking a wide 
range of antihypertensive medications. The TIME meth-
odology facilitates the collection of additional partici-
pant-reported information like this to answer related 
research questions with minimal additional resources. 
The TIME Sleep substudy will be a very large study of 
sleep quality and duration in treated hypertensive adults 
that uses an online methodology to efficiently combine 
PROM data with clinical outcomes.
If the TIME study does show clinically significant bene-
fits of dosing antihypertensive medication in the evening, 
this would represent a very cost-effective advance in the 
treatment of hypertension and the prevention of cardio-
vascular disease. However, successful implementation 
of any dosing time guidance based on the TIME results 
will depend on whether the dosing time is acceptable to 
patients. Sleep quality may play an important role in this 
assessment.
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